Pre-treatment of human osteosarcoma cells with N-methylformamide enhances P-glycoprotein expression and resistance to doxorubicin.
Int J Cancer
; 58(1): 95-101, 1994 Jul 01.
Article
en En
| MEDLINE
| ID: mdl-7912235
ABSTRACT
N-methylformamide (NMF), a powerful differentiating agent, has been extensively used in experimental and preclinical cancer chemotherapy studies, alone or in association with conventional anti-cancer drugs. To evaluate the use of this molecule in the treatment of osteosarcoma (OS), we have analyzed the effects of NMF and doxorubicin (DXR) on DXR-sensitive and -resistant human OS cell lines. Our study shows that NMF exerts remarkable effects on cell proliferation and, in Saos-2 and SARG cells, also induces differentiation, as shown by increasing alkaline phosphatase activity. Moreover, NMF increases the cytotoxic activity of DXR when administered after the drug, in both DXR-sensitive and -resistant cells. However, when this agent is given before DXR, it enhances P-glycoprotein expression in U-2 OS cell lines. This over-expression is associated with reduced DXR accumulation within cells and with significant enhancement of resistance to DXR.
Buscar en Google
Colección:
01-internacional
Asunto principal:
Neoplasias Óseas
/
Glicoproteínas de Membrana
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Proteínas Portadoras
/
Doxorrubicina
/
Osteosarcoma
/
Formamidas
/
Antineoplásicos
Límite:
Humans
Idioma:
En
Revista:
Int J Cancer
Año:
1994
Tipo del documento:
Article
País de afiliación:
Italia